Stock ASRT ASSERTIO HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Assertio Holdings, Inc.

Equities

ASRT

US04546C2052

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.8282 USD +5.49% Intraday chart for Assertio Holdings, Inc. +7.14% -22.60%
Apr. 02 James L. Tyree, Chairman of the Compensation Committee of the Board of Directors of Assertio Holdings, Inc. Declines to Stand for Reelection CI
Mar. 12 Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 100.9 38.34 97.3 207.7 101.3 78.78 -
Enterprise Value (EV) 1 100.9 101.7 97.3 207.7 101.3 78.78 78.78
P/E ratio -0.41 x -1.32 x -72.7 x 2.12 x -0.23 x -6.9 x 166 x
Yield - - - - - - -
Capitalization / Revenue 0.44 x 0.36 x 0.88 x 1.33 x 0.67 x 0.67 x 0.61 x
EV / Revenue 0.44 x 0.36 x 0.88 x 1.33 x 0.67 x 0.67 x 0.61 x
EV / EBITDA - 1.71 x 1.99 x 2.04 x 1.5 x 3.26 x 1.67 x
EV / FCF 1.13 x - -7.48 x 2.65 x 2.07 x 4.33 x 2.37 x
FCF Yield 88.2% - -13.4% 37.7% 48.3% 23.1% 42.3%
Price to Book - - - 0.92 x - - -
Nbr of stocks (in thousands) 20,170 26,806 44,634 48,294 94,669 95,122 -
Reference price 2 5.000 1.430 2.180 4.300 1.070 0.8282 0.8282
Announcement Date 3/9/20 3/11/21 3/9/22 3/8/23 3/11/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 229.5 106.3 111 156.2 152.1 117.4 130.1
EBITDA 1 - 22.41 48.83 101.6 67.74 24.2 47.23
EBIT 1 137.2 20.76 19.75 39.4 -243.5 -12.77 2.173
Operating Margin 59.79% 19.54% 17.79% 25.22% -160.15% -10.88% 1.67%
Earnings before Tax (EBT) 1 - - -0.553 31.17 -254.1 -13.72 1.173
Net income 1 -217.2 -28.14 -1.281 109.6 -331.9 -11.75 1.78
Net margin -94.64% -26.48% -1.15% 70.17% -218.28% -10.01% 1.37%
EPS 2 -12.28 -1.080 -0.0300 2.030 -4.670 -0.1200 0.005000
Free Cash Flow 1 88.99 - -13 78.32 48.98 18.17 33.3
FCF margin 38.78% - -11.71% 50.13% 32.21% 15.49% 25.59%
FCF Conversion (EBITDA) - - - 77.09% 72.3% 75.1% 70.5%
FCF Conversion (Net income) - - - 71.45% - - 1,871.03%
Dividend per Share - - - - - - -
Announcement Date 3/9/20 3/11/21 3/9/22 3/8/23 3/11/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 25.47 33.33 36.54 35.13 34.21 50.35 42.47 40.99 35.63 32.98 29.51 29.81 28.61 29.41 -
EBITDA 1 15.8 17.83 23.86 22.91 21.44 33.38 25.6 24.77 12.91 4.451 5.72 7.07 5.623 5.178 -
EBIT 1 8.385 10.45 11.56 10.79 6.434 10.62 4.644 12.42 13.59 -32.33 -3.203 -2.49 -3.698 -3.378 4.083
Operating Margin 32.92% 31.35% 31.64% 30.72% 18.81% 21.09% 10.94% 30.3% 38.16% -98.01% -10.85% -8.35% -12.92% -11.48% -
Earnings before Tax (EBT) 1 3.783 5.042 9.777 8.427 4.384 8.576 -5.594 12.33 -228.9 -31.9 -3.453 -2.74 -3.948 -3.628 3.383
Net income 1 3.737 4.609 9.064 7.834 4.174 88.55 -3.484 8.47 -279.5 -57.38 -2.928 -2.406 -3.324 -3.096 3.214
Net margin 14.67% 13.83% 24.81% 22.3% 12.2% 175.86% -8.2% 20.66% -784.64% -173.97% -9.92% -8.07% -11.62% -10.53% -
EPS 2 0.0800 0.1000 0.2000 0.1600 0.0800 1.340 -0.0700 0.1300 -3.420 -0.6100 -0.0300 -0.0250 -0.0350 -0.0300 0.0300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 3/9/22 5/9/22 8/8/22 11/8/22 3/8/23 5/9/23 8/3/23 11/8/23 3/11/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - 63.3 - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - 2.825 x - - - - -
Free Cash Flow 1 89 - -13 78.3 49 18.2 33.3
ROE (net income / shareholders' equity) - - - 39.5% -183% -2.8% 12.2%
ROA (Net income/ Total Assets) - - - 17.5% -94.8% -1.4% 6.6%
Assets 1 - - - 626 350.2 839.4 26.96
Book Value Per Share - - - 4.670 - - -
Cash Flow per Share - - - - - - -
Capex 1 - - - 0.27 0.63 2 2
Capex / Sales - - - 0.18% 0.41% 1.7% 1.54%
Announcement Date 3/9/20 3/11/21 3/9/22 3/8/23 3/11/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Assertio Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8282 USD
Average target price
3 USD
Spread / Average Target
+262.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASSERTIO HOLDINGS, INC. Stock Assertio Holdings, Inc.
-22.60% 78.78M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ASRT Stock
  4. Financials Assertio Holdings, Inc.